Stephen K. M.D. Klasko Sells 200 Shares of Teleflex Incorporated (TFX) Stock
Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $237.18, for a total value of $47,436.00. Following the completion of the transaction, the director now owns 8,080 shares of the company’s stock, valued at $1,916,414.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Teleflex Incorporated (NYSE:TFX) traded up $1.61 on Friday, hitting $256.41. The stock had a trading volume of 439,046 shares, compared to its average volume of 227,863. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 2.76. The company has a market capitalization of $11,551.01, a P/E ratio of 31.69, a P/E/G ratio of 2.46 and a beta of 1.05.
Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The company had revenue of $534.70 million during the quarter, compared to the consensus estimate of $522.94 million. During the same period last year, the company earned $1.80 earnings per share. The firm’s revenue was up 17.3% compared to the same quarter last year. sell-side analysts anticipate that Teleflex Incorporated will post 8.31 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.53%. Teleflex’s dividend payout ratio (DPR) is 24.82%.
COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/stephen-k-m-d-klasko-sells-200-shares-of-teleflex-incorporated-tfx-stock-2/1680362.html.
Several institutional investors and hedge funds have recently modified their holdings of TFX. Janus Henderson Group PLC raised its position in shares of Teleflex by 50,429.2% during the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock worth $377,296,000 after acquiring an additional 1,812,426 shares during the last quarter. Koch Industries Inc. raised its position in shares of Teleflex by 47,174.3% during the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock worth $955,000 after acquiring an additional 957,639 shares during the last quarter. American Century Companies Inc. raised its position in shares of Teleflex by 41.6% during the third quarter. American Century Companies Inc. now owns 1,187,909 shares of the medical technology company’s stock worth $287,438,000 after acquiring an additional 348,829 shares during the last quarter. Marshall Wace North America L.P. raised its position in shares of Teleflex by 137.4% during the second quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock worth $107,840,000 after acquiring an additional 300,069 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Teleflex by 93.5% during the second quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock worth $126,816,000 after acquiring an additional 294,935 shares during the last quarter. Institutional investors own 89.78% of the company’s stock.
Several research firms have commented on TFX. Morgan Stanley increased their target price on Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research report on Friday. Jefferies Group LLC increased their target price on Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research report on Friday. Needham & Company LLC increased their target price on Teleflex from $237.00 to $285.00 and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Stephens reiterated a “buy” rating and issued a $270.00 target price (up from $230.00) on shares of Teleflex in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $271.88.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.